<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04556578</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19-0548</org_study_id>
    <nct_id>NCT04556578</nct_id>
  </id_info>
  <brief_title>Use of Extracorporeal CO2 Removal in Case of Moderate to Severe ARDS to Apply an Ultraprotective Mechanical Ventilation Strategy</brief_title>
  <acronym>ECCO2R</acronym>
  <official_title>Use of Extracorporeal CO2 Removal in Case of Moderate to Severe Acute Respiratory Distress Syndrome to Apply an Ultraprotective Mechanical Ventilation Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The extracorporeal CO2 removal (ECCO2R) has been recently proposed in case of Acute&#xD;
      Respiratory Distress Syndrome (ARDS) in order to reduce pulmonary injuries induced by the&#xD;
      mechanical ventilation. A reducing of tidal volume and/or respiratory rate is thus expected&#xD;
      using this extracorporeal respiratory support. However, most of existing devices of ECCO2R&#xD;
      can apply only a limited extracorporeal flow, often less than 1L/min, which limits the CO2&#xD;
      exchanges and does not allow to reach an ultraprotective ventilation. An extracorporeal flow&#xD;
      higher should logically maximalize CO2 removal and allow reducing intensity of mechanical&#xD;
      ventilation. Works focused on high-flow ECCO2R (2-3 L/min) in setting of ARDS are therefore&#xD;
      mandatory to better understand apprehend the phenomena of gazes changes with this device and&#xD;
      confirm the added-value in management of these specific patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective interventional study focused on a cohort population.&#xD;
&#xD;
      The included patients will be those affected by a severe ARDS (Berlin definition) requiring&#xD;
      an aggressive mechanical ventilation and whom a high-flow ECCO2R was implemented.&#xD;
&#xD;
      The high-flow ECCO2R will be proposed in all patients with inclusions criteria with the 15&#xD;
      first days following their admission. The day of initiation of the high-flow ECCO2R will&#xD;
      considered as Day 0 in our study.&#xD;
&#xD;
      A data collection will be focused on the respiratory parameters, clinical complications until&#xD;
      ICU discharge and outcome, extracted from medical records.&#xD;
&#xD;
      The main endpoint will be the perrcentage of patients whom an ultraprotective ventilation&#xD;
      could be applied successfully during more than 12h. Ultraprotective ventilation is defined in&#xD;
      our work as follows: Tidal volume ≤ 3 mL/kg and respiratory rate ≤ 16/min associated with a&#xD;
      PaCO2 ≤ 45mmHg and a PaO2 ≥ 55 mmHg.&#xD;
&#xD;
      The secondary endpoints will be durations of mechanical ventilation, ICU stay and&#xD;
      hospitalization, as well as rheological behavior of extracorporeal circulation, respiratory&#xD;
      parameters under high-flow ECCO2R, specific complications and mortality.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patient who obtained a safe ultraprotective ventilation</measure>
    <time_frame>12 hours</time_frame>
    <description>a safe ultraprotective ventilation is defined by the four following parameters :&#xD;
Tidal Volume ≤ 3 mL/kg&#xD;
Respiratory Rate ≤ 16/min&#xD;
PaCO2 ≤ 45mmHg&#xD;
PaO2 ≥ 55 mmHg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>up to Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 30 all-cause mortality</measure>
    <time_frame>up to Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acue Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>High-flow ECCO2R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extracorporeal support using high flow circulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High-flow extracorporeal CO2 removal</intervention_name>
    <description>Applying of a CO2 removal using an extracorporeal circulation with a flow of 2-3.5L/min in order to reduce the aggression induced by the mechanical ventilation.</description>
    <arm_group_label>High-flow ECCO2R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged from 18 years old&#xD;
&#xD;
          -  Patient suffering from ARDS including the 3 following parameters during more than 12&#xD;
             hours:&#xD;
&#xD;
        PaO2/FiO2 ≤200 Driving Pressure ≥15 cmH2O, Tidal Volume = 6 mL/kg PIT Respiratory rate ≥&#xD;
        28/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients protected by law (Art.L 1121-5, 1121-6, 1121-8 du Code de la santé publique)&#xD;
&#xD;
          -  Consent refusal from the patient or his/her next of kin and the impossibility to enrol&#xD;
             using the emergency procedure&#xD;
&#xD;
          -  Pregnant or breast feeding patient&#xD;
&#xD;
          -  Absence of a French Health Care Insurance coverage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan Charbit, MD</last_name>
    <phone>+33467338256</phone>
    <email>j-charbit@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital of Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jonathan CHARBIT, MD</last_name>
    </contact>
    <contact_backup>
      <phone>+33467338256</phone>
      <email>j-charbit@chu-montpellier.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan CHARBIT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2020</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS</keyword>
  <keyword>ECCO2R</keyword>
  <keyword>Ultraprotective ventilation</keyword>
  <keyword>Respiratory extracorporeal support</keyword>
  <keyword>Mechanical power</keyword>
  <keyword>Driving pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>identified data used in the published manuscript will be shared in accordance with the applicable informed consent under which the data was collected</ipd_description>
    <ipd_time_frame>12 months after the main publication</ipd_time_frame>
    <ipd_access_criteria>Data are provided to qualified investigators free of charge. Required documents to request data include a summary of the research plan, request form, and IRB review. Dataset will be shared after careful examination by the study board of investigators.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

